N8 Medical Press Releases

• Published on September 4, 2024 - 08:02 GMT

  N8 Medical to present at the World Antimicrobial Congress

  Preventing Biofilm Fouling of Medical Devices Can Be An Effective and Near Term Solution to the crisis of hospital acquired infections. DUBLIN, OH, UNITED STATES, September 4, 2024 /⁨EINPresswire.com⁩/ -- N8 Medical, LLC (N8”), a clinical-stage at the …

  Distribution channels: Healthcare & Pharmaceuticals Industry, International Organizations ...
• Published on July 23, 2024 - 12:08 GMT

  

  FDA Grants QIDP Designation to Kinnear Pharma for treatment of Acinetobacter baumannii Infections

  FDA QiDP designation is the 4th issued to Kinnear establishing Kinnear as a leader in the fight against antimicrobial resistance (AMR). PARK CITY, UTAH, UNITED STATES, July 23, 2024 /⁨EINPresswire.com⁩/ -- Kinnear Pharmaceuticals, LLC and Kinnear Pharma …

  Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
• Published on July 18, 2024 - 10:26 GMT

  

  Groundbreaking Research on Ceragenins for Combatting Life-Threatening Acinetobacter baumannii Infections

  Ceragnins -- Novel Class of Potent Anti-Infectives --- address the AMR crisis PARK CITY, UT, UNITED STATES, July 18, 2024 /⁨EINPresswire.com⁩/ -- N8 Medical Inc. and its drug subsidiaries Kinnear Pharmaceuticals, LLC and Kinnear Pharma AUS Pty Ltd are …

  Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
• Published on November 15, 2023 - 13:35 GMT

  

  FDA Grants QIDP Designation for Drug to Treat Candida Auris and Aspergillus fungal infections

  This is the second QIDP Designation granted to Kinnear Pharmaceuticals PARK CITY, NV, UNITED STATES, November 15, 2023 /⁨EINPresswire.com⁩/ -- FDA grants QIDP Designation For Kinnear’s CSA-131 drug for Life-threatening Candida auris and Aspergillus fungal …

  Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
• Published on August 17, 2023 - 13:00 GMT

  

  N8 Medical and USAMRIID Enter CRADA to Test CSA Compounds Against Anthrax and other Biodefense Pathogens

  N8Medical has entered into a CRADA with USAMRIID in support of Core Antibiotic Screening Program. Will test CSAs against biodefense pathogens including Anthrax. PARK CITY, UTAH, UNITED STATES OF AMERICA, August 17, 2023 /⁨EINPresswire.com⁩/ -- USAMRIID …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Military Industry ...
• Published on July 31, 2023 - 12:15 GMT

  

  FDA grants QIDP Designation For Kinnear's CSA-131 drug for Life-threatening Pseudomonas Bacterial Infections in CF

  FDA QiDP designation is a signifcant milestone PARK CITY, UTAH, UNITED STATES, July 31, 2023 /⁨EINPresswire.com⁩/ -- Kinnear Pharmaceuticals, LLC, a subsidiary of N8 Medical, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted …

  Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
• Published on June 22, 2022 - 17:13 GMT

  N8 Medical Is Awarded Almost $2 Million in Phase II SBIR Grant

  Grant Funding will Support Further Development of Antimicrobial Pacemaker Envelope PARK CITY, UTAH, UNITED STATES, June 22, 2022 /⁨EINPresswire.com⁩/ -- N8 Medical Is Awarded Almost $2 Million in Phase II SBIR Grant N8 Medical, Inc. (the “Company”) …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on March 10, 2022 - 00:08 GMT

  

  N8 Medical's CeraShield Endotracheal Tube my prevent potentially lethal respiratory infections in ICU patients

  A newly funded clinical study's results may change the practice of ICU care. SALT LAKE CITY, UTAH, UNITED STATES, March 9, 2022 /⁨EINPresswire.com⁩/ -- Can N8 Medical’s CeraShield Endotracheal Tube prevent potentially lethal respiratory infections in …

  Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
• Published on November 15, 2021 - 17:14 GMT

  N8 Medical Obtains Brazilian Regulatory Approval for its CeraShield Infection Prevention ® Endotracheal Tube

  Medical Device is Designed To Prevent Potentially Lethal Complications and Reduce Cost of Care in Patients who Require Mechanical Ventilation in ICUs. DUBLIN, OHIO, USA, November 15, 2021 /⁨EINPresswire.com⁩/ -- N8 Medical Obtains Brazilian Regulatory …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Technology ...
• Published on September 29, 2021 - 11:05 GMT

  Robert D. Mitchell is new Chief Executive Officer at N8 Medical

  DUBLIN, OHIO, UNITED STATES, September 29, 2021 /⁨EINPresswire.com⁩/ -- Robert D. Mitchell is new Chief Executive Officer at N8 Medical Jay Golding elected Chairman of the Board N8 Medical (“N8”) announces the hiring of industry veteran Robert D. …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...